ADORA2A and adenocarcinoma: When only patients with adenocarcinoma who had been tested for EGFR alterations using standard methods (N = 186) were investigated, however, both the CD73 and A2AR expression levels remained significantly higher in EGFR-mutant tumors than in EGFR-wild type tumors (P < 0.0001 for CD73 and P = 0.0010 for A2AR).